Witryna1 mar 2024 · Impel NeuroPharma, Inc. is a privately held, Seattle -based pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize … Witryna11 lut 2024 · Impel adopting Veeva software, data, and consulting to accelerate pre-launch planning and digital-first commercial execution. SEATTLE and PLEASANTON, CA — February 10, 2024 — Impel NeuroPharma and Veeva Systems (NYSE: VEEV) today announced a strategic partnership as Impel continues advancing its pipeline of …
Impel NeuroPharma Announces First Quarter 2024 Financial …
WitrynaSenior Scientist. Impel NeuroPharma. Feb 2024 - Present1 year 2 months. Seattle. Oversee analytical method development, transfer … Witryna25 kwi 2024 · SEATTLE, April 25, 2024 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing … mineral groups on periodic table
Impel Neuropharma to Present Pivotal, Phase 3 Data From STOP …
WitrynaImpel NeuroPharma. Sep 2024 - Present1 year 8 months. Salt Lake City, Utah, United States. Launch of a new migraine product with Impel, I cover the greater SLC territory and north up to Idaho ... Witryna7 cze 2024 · SEATTLE, June 07, 2024 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage pharmaceutical company focused on utilizing its proprietary POD ® technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, today reported … Witryna12 kwi 2024 · According to the issued ratings of 2 analysts in the last year, the consensus rating for Impel Pharmaceuticals stock is Moderate Buy based on the current 1 hold rating and 1 buy rating for IMPL. The average twelve-month price prediction for Impel Pharmaceuticals is $21.25 with a high price target of $40.00 and a low price target of … mineral group of gold